Indications
Therapeutic Asset Ratings
3,272 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tak-243
Myelodysplastic Syndrome
National Cancer Institute (NCI)
P1
CC
(43)
Tak-243
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Tazemetostat
Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
National Cancer Institute (NCI)
P1
CC
(43)
Tazemetostat
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
P1
CC
(43)
Tazemetostat Hydrobromide
Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Tcr Transduced T-Cells
Myelodysplastic Syndrome
National Cancer Institute (NCI)
P1
CC
(43)
Tcr Transduced T-Cells
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Tcr Transduced T-Cells
Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P1
CC
(43)
Tcr Transduced T-Cells
Hematopoietic And Lymphoid System Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Tcr Transduced T-Cells
Acute Myeloid Leukemia
National Cancer Institute (NCI)
P1
CC
(43)
Teclistamab
Plasmablastic Lymphoma
National Cancer Institute (NCI)
P1
CC
(43)
Telaglenastat
Astrocytoma, IDH-Mutant, Grade 2
National Cancer Institute (NCI)
P1
CC
(43)
Telaglenastat
Astrocytoma, IDH-Mutant, Grade 3
National Cancer Institute (NCI)
P1
CC
(43)
Telaglenastat
Malignant Leptomeningeal Tumor
National Cancer Institute (NCI)
P1
CC
(43)
Telaglenastat
Metastatic Malignant Neoplasm In The Brain
National Cancer Institute (NCI)
P1
CC
(43)
Tnhyp217 Car T Cells
Thymus Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Tolinapant
Breast Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Tolinapant
Invasive Breast Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Tolinapant
Hormone Receptor-Positive Breast Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Tolinapant
Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Trastuzumab Deruxtecan
Gastric Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Trastuzumab Deruxtecan
Salivary Gland Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Trastuzumab Deruxtecan
Hepatobiliary Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Trastuzumab Deruxtecan
Colon Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Trastuzumab Deruxtecan
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Showing 3001 to 3025 of 3,272 assets
Previous
Page 121 of 131
Next
